The Bull Rankings scorecard — our quality-growth score is 76.6 / 100, built from three pillars scored 0–100: Quality 78, Growth 91, Value 64 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 18% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Veeva’s price is a fair bet on continued revenue acceleration. The Bull Rankings model gives the stock a 76.6/100 quality‑growth score, with Growth at 91 and Value at 64. Growth is the story here: the company is pulling in 16.5% YoY revenue growth and a 29.3% profit margin that keeps earnings healthy. The model’s reverse‑DCF says the current share price implies free‑cash‑flow growth of about 18% in year 1, tapering to 4% by year 10—a trajectory that sits comfortably above the trailing revenue growth but not wildly optimistic. In short, the market is pricing in a modest acceleration that our data supports, and the stock is not yet over‑priced relative to peers.
What the business actually is
Veeva sells cloud‑based software to the life sciences sector. Its flagship Veeva Commercial Cloud bundles the Vault CRM Suite, Medical, PromoMats, and Crossix analytics, all designed for pharmaceutical and biotechnology companies. On the data side, Veeva offers OpenData, Link, and Compass—customer reference, deep‑data, and compliance solutions. These products serve global customers across North America, Europe, APAC, MENA, and LATAM, driving the company’s recurring revenue engine.
Why it can (or can't) keep compounding
The moat is built on platform lock‑in and high switching costs. The Vault CRM Suite and Medical content ecosystem are tightly integrated; once a pharma client embeds Veeva’s data and workflows, moving to a rival requires a costly rebuild. Margins stay high at 29.3%, and free cash flow of $1.7 b shows the business can fund growth internally. Debt‑to‑equity of 0.02 signals a clean balance sheet, allowing Veeva to pursue acquisitions or new product lines without diluting shareholders. Competitors struggle to replicate the breadth of Veeva’s end‑to‑end solution—especially the analytics and data layers—so the company can keep compounding its revenue base.
The valuation question
At a P/E of 46.5, Veeva sits in the 90th percentile among healthcare peers, indicating the market is willing to pay a premium for its growth. The reverse‑DCF implied growth of 18% in the first year is only slightly above the actual 16.5% revenue growth, suggesting the price already assumes a modest acceleration. If the company can sustain or lift that 18% trajectory, the valuation remains justified; if it stalls, the premium erodes. The PEG ratio of 1.05 shows the market is not yet demanding a high growth premium relative to earnings, keeping the price from looking over‑ambitious.
The bear case
The weakest pillar in the model is Value at 64. While not a red flag, it signals that the stock is not the cheapest in its sector. If revenue growth were to dip below 16.5%—for example, if a key customer churns or regulatory delays slow new product launches—the implied free‑cash‑flow growth would fall below the 18% the price assumes. A drop in margin below 29.3% would also compress earnings, making the P/E less defensible. The recent news of EVP Daniel Rizzo selling 4,841 shares and other institutional sell‑offs could hint at internal concerns, though the data does not show a systemic issue.
What would change our mind
- Revenue growth falling below 15% YoY would invalidate the 18% implied growth, turning the premium into a bubble.
- Profit margin slipping under 25% would erode earnings and push the P/E higher than justified.
- Value pillar dropping below 50—meaning the stock becomes the most expensive relative to peers—would signal that the market has over‑priced the growth story.
If any of these thresholds are breached, the thesis would shift from a justified growth bet to a cautionary stance.